Expression of GFAP was reduced (nonsense versus shRNA CgA, 1.0±0.1 versus 0.02±0.01, P<0.05, Fig. 2B), whereas expression of PMP22 (1.0±0.02 versus 3.3±0.5, P<0.05, Fig. 2C) and SERPINF1 (1.0±0.1 versus 3.1±0.5, P<0.01, Fig. 2C) was increased in the shRNA CgA transfectants compared to nonsense control neuroblastoma cells. The gene discussed is GFAP; the disease is neuroblastoma.